NCT01480141View on ClinicalTrials.gov

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

January 31, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions

Lung Cancer

Interventions

DRUG

BIBW 2992 (Afatinib)

Patients will receive treatment with afatinib 40mg orally daily for a minimum of 2 weeks

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Medical University of South Carolina

OTHER

NCT01480141 - A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter